Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongmin Kim

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Vaccine|March 24, 2016
Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain KSeung Bin Cha, Woo Sik Kim, Jong-Seok Kim, et al.
Oncotarget|February 15, 2017
Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in miceHan-Gyu Choi, Seunga Choi, Yong Woo Back, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2020
Immunization with <i>Mycobacterium tuberculosis</i>-Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guérin Vaccination and Improves Protection in MiceClaus Aagaard, Niels Peter Hell Knudsen, Iben Sohn, et al.
Oncotarget|April 21, 2016
Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strainWoo Sik Kim, Jong-Seok Kim, Seung Bin Cha, et al.
Vaccine|December 22, 2019
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosisFlorence Levillain, Hongmin Kim, Kee Woong Kwon, et al.
Infection and Immunity|October 9, 2019
Construction and Characterization of the Mycobacterium tuberculosis <i>sigE fadD26</i> Unmarked Double Mutant as a Vaccine CandidateRogelio Hernandez-Pando, Sung Jae Shin, Simon Clark, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Vaccine|March 24, 2016
Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain KSeung Bin Cha, Woo Sik Kim, Jong-Seok Kim, et al.
Oncotarget|February 15, 2017
Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in miceHan-Gyu Choi, Seunga Choi, Yong Woo Back, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2020
Immunization with <i>Mycobacterium tuberculosis</i>-Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guérin Vaccination and Improves Protection in MiceClaus Aagaard, Niels Peter Hell Knudsen, Iben Sohn, et al.
Oncotarget|April 21, 2016
Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strainWoo Sik Kim, Jong-Seok Kim, Seung Bin Cha, et al.
Vaccine|December 22, 2019
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosisFlorence Levillain, Hongmin Kim, Kee Woong Kwon, et al.
Infection and Immunity|October 9, 2019
Construction and Characterization of the Mycobacterium tuberculosis <i>sigE fadD26</i> Unmarked Double Mutant as a Vaccine CandidateRogelio Hernandez-Pando, Sung Jae Shin, Simon Clark, et al.
Pageof 4